PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Ann Oncol. 2018 Oct 1;29(10):2151. doi: 10.1093/annonc/mdx803.
No abstract available

Publication types

  • Published Erratum